MTOR and neoplasm: Our group had previously developed a dual-target PI3K/mTOR inhibitor YYN-37, characterized by notable anti-tumor activities both in vitro and in vivo, good kinase selectivity, minimal hepatotoxic effects, moderate plasma clearance rates, and satisfactory oral bioavailability [20].